PREVENTION OF CARDIOVASCULAR DISEASE IN DIABETES MELLITU

预防糖尿病中的心血管疾病

• 批准号: 6191630
• 负责人: Richard Hugo Grimm
• 金额: $ 42.07万
• 依托单位: HENNEPIN HEALTHCARE RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-09-30 至 2008-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6191630
• 关键词: antihyperlipoproteinemic agent; antihypertensive agents; blood glucose; blood lipid; blood pressure; cardiovascular disorder prevention; clinical research; combination chemotherapy; comorbidity; counseling; diabetes mellitus therapy; disease /disorder proneness /risk; health care cost /financing; human middle age (35-64); human old age (65+); human subject; human therapy evaluation; hypoglycemic agents; insulin sensitivity /resistance; longitudinal human study; noninsulin dependent diabetes mellitus; quality of life

Most diabetic patients die of cardiovascular disease (CVD), with CVD rates in diabetic persons two to four times those of the non-diabetic population. This increased CVD risk, along with the increasing prevalence of obesity and increasing numbers of elderly in the U.S. population, means that diabetes-associated CVD will become an even greater public health problem in the future. Diabetes mellitus is a complex metabolic disorder with generally evaluated levels of insulin resistance and variable levels of circulating insulin, which is often accompanied by abnormalities in carbohydrate, lipid, and protein metabolism and elevated blood pressure. While glucose control appears important for Type 2 patients, it is critical not to overlook treatment of associated CVD risk factor abnormalities. The effects on prevention of cardiovascular disease events of intensive control of established CVD risk factors (blood pressure and blood lipids), and intensive control of blood glucose, in Type 2 diabetes are unknown. The study is a multi-center randomized clinical trial of about 10,000 adult patients with Type 2 diabetes mellitus followed for four to seven years. The primary objective of this research program is to assess whether the rate of major cardiovascular disease events can be reduced by: (1) intensive control of blood sugar compared with conventional control; (2) intensive control of blood pressure compared with conventional control; and (3) intensive control of blood lipids compared with conventional control. Other objectives include the comparative cost effectiveness of the above interventions and their impact on health-related quality of life.

大多数糖尿病患者死于心血管疾病（CVD），糖尿病患者的CVD率是非糖尿病人群的两到四倍。这种CVD风险增加，加上肥胖症的越来越多，在美国人口中的老年人数量增加，这意味着将来与糖尿病相关的CVD将来将成为更大的公共卫生问题。糖尿病是一种复杂的代谢疾病，具有普遍评估的胰岛素抵抗水平和可变水平的循环胰岛素，通常伴有碳水化合物，脂质和蛋白质代谢和升高血压的异常。虽然控制葡萄糖对2型患者似乎很重要，但至关重要的是不要忽视相关CVD风险因素异常的治疗。在2型糖尿病中，对已建立的CVD危险因素（血压和血脂）进行密集控制的心血管疾病事件的影响以及对血糖的密集控制的影响尚不清楚。这项研究是一项多中心随机临床试验，对大约10,000名2型糖尿病患者进行了四到七年。该研究计划的主要目的是评估主要心血管疾病事件的发生率是否可以通过以下方式降低：（1）与常规对照相比，对血糖的密集控制； （2）与常规对照相比，密集控制血压； （3）与常规对照相比，对血脂的密集控制。其他目标包括上述干预措施的比较成本效益及其对与健康相关的生活质量的影响。